Evidence map›Paper›PMID 37774771›Full record

SynthesisTechnology in cancer research & treatment

Adoption of Hybrid MRI-Linac Systems for the Treatment of Brain Tumors: A Systematic Review of the Current Literature Regarding Clinical and Technical Features.

Andrea Emanuele Guerini, Stefania Nici, Stefano Maria Magrini, Stefano Riga, Cristian Toraci, Ludovica Pegurri, Giorgio Facheris, Claudia Cozzaglio, Davide Farina, Roberto Liserre and 5 more

Open access · goldAbstract readSystematic Review
In one paragraph

Synthesis in Technology in cancer research & treatment. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
3.9field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Review
  7. Article
  8. Article
  9. Article
  10. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors at 3 institutions in 2 countries.

Andrea Emanuele GueriniDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Stefania NiciMedical Physics Department, ASST Spedali Civili Hospital, Brescia, Italy.
Stefano Maria MagriniDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Stefano RigaMedical Physics Department, ASST Spedali Civili Hospital, Brescia, Italy.
Cristian ToraciMedical Physics Department, ASST Spedali Civili Hospital, Brescia, Italy.
Ludovica PegurriDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Giorgio FacherisDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.ORCID 0000-0002-4555-1725
Claudia CozzaglioDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.
Davide FarinaRadiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Roberto LiserreDepartment of Radiology, Neuroradiology Unit, ASST Spedali Civili University Hospital, Brescia, Italy.
Roberto GasparottiNeuroradiology Unit, Department of Medical-Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Marco RavanelliRadiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Paolo RondiRadiology Unit, Department of Medical and Surgical Specialties, Radiological Sciences and Public Health, University of Brescia, Brescia, Italy.
Luigi SpiazziMedical Physics Department, ASST Spedali Civili Hospital, Brescia, Italy.
Michela BuglioneDepartment of Radiation Oncology, University and Spedali Civili Hospital, Brescia, Italy.ORCID 0000-0002-5485-1260
Azienda Socio Sanitaria Territoriale degli Spedali Civili di Brescia · ITUniversity of Brescia · ITHealth First · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundPossible advantages of magnetic resonance (MR)-guided radiation therapy (MRgRT) for the treatment of brain tumors include improved definition of treatment volumes and organs at risk (OARs) that could allow margin reductions, resulting in limited dose to the OARs and/or dose escalation to target volumes. Recently, hybrid systems integrating a linear accelerator and an magnetic resonance imaging (MRI) scan (MRI-linacs, MRL) have been introduced, that could potentially lead to a fully MRI-based treatment workflow.

methodsWe performed a systematic review of the published literature regarding the adoption of MRL for the treatment of primary or secondary brain tumors (last update November 3, 2022), retrieving a total of 2487 records; after a selection based on title and abstracts, the full text of 74 articles was analyzed, finally resulting in the 52 papers included in this review. RESULTS AND DISCUSSION: Several solutions have been implemented to achieve a paradigm shift from CT-based radiotherapy to MRgRT, such as the management of geometric integrity and the definition of synthetic CT models that estimate electron density. Multiple sequences have been optimized to acquire images with adequate quality with on-board MR scanner in limited times. Various sophisticated algorithms have been developed to compensate the impact of magnetic field on dose distribution and calculate daily adaptive plans in a few minutes with satisfactory dosimetric parameters for the treatment of primary brain tumors and cerebral metastases. Dosimetric studies and preliminary clinical experiences demonstrated the feasibility of treating brain lesions with MRL.

conclusionsThe adoption of an MRI-only workflow is feasible and could offer several advantages for the treatment of brain tumors, including superior image quality for lesions and OARs and the possibility to adapt the treatment plan on the basis of daily MRI. The growing body of clinical data will clarify the potential benefit in terms of toxicity and response to treatment.

Indexed as

Brain NeoplasmsRadiotherapy Planning, Computer-AssistedHumansMagnetic Resonance ImagingMagnetic Resonance SpectroscopyParticle AcceleratorsRadiotherapy Dosagebrain tumorsglioblastomaMR-guided radiation therapyMRI-linacradiotherapyreview

Identifiers

PMID37774771
PMCPMC10542234
OpenAlexW4387197685

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.